Product Description
Pfizer is developing PF-04995274 as a treatment for Unipolar Depression. (Sourced from: https://clinicaltrials.gov/study/NCT03516604)
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Depressive Disorder|Alzheimer Disease|Depressive Disorder, Treatment-Resistant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RESTAND | P1 |
Completed |
Depressive Disorder |
2022-07-29 |
72% |
2022-11-04 |
Primary Endpoints|Treatments|Trial Status |
| RESTART | P1 |
Completed |
Depressive Disorder, Treatment-Resistant |
2022-07-26 |
2022-11-05 |
Primary Endpoints|Treatments|Trial Status |
|
| B1661006 | P1 |
Terminated |
Alzheimer Disease |
2011-07-01 |
2019-03-19 |
Treatments |
|
| B1661004 | P1 |
Completed |
Healthy Volunteers |
2011-01-01 |
2019-03-19 |
Treatments |
|
| B1661003 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
2019-03-19 |
Treatments |
|
| B1661002 | P1 |
Completed |
Healthy Volunteers |
2010-11-01 |
2019-03-19 |
Treatments |
|
| B1661001 | P1 |
Completed |
Healthy Volunteers |
2010-08-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|